Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population in the country. Although the treatment of acute heart failure (AHF) is dominated by older, cost-effective generic drugs, we expect the growing uptake of recently approved SGLT-2 inhibitors—dapagliflozin (Bristol Myers Squibb’s Farxiga) and empagliflozin (Boehringer Ingelheim’s Jardiance)—to boost the heart failure market. However, a significant unmet need exists for the treatment of chronic heart failure (CHF) with preserved ejection fraction, where treatment options are limited, representing an opportunity for drug developers. In addition, the ongoing reforms in the regulatory and A&R landscape of China are expected to encourage MNCs to enter the heart failure market.
- How large is China’s drug-treatable heart failure population, and how will the drug-treatment rate change during the forecast period?
- What are the most commercially relevant drugs in China’s heart failure market, and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the heart failure pipeline in China? What sales/uptake could they secure in heart failure?
- What are the key drivers and constraints in the Chinese heart failure market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with cardiologists Supported by survey data collected for this and other DRG research epidemiology Diagnosed prevalence of heart failure in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key heart failure regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 5+ drugs; Phase II: 3 drugs; coverage of select Phase I products
- Heart Failure | China In-Depth | China
- China In-Depth: Heart Failure
Author(s): Akash Saini, PhD; Sunali D. Goonesekera, SM
Akash is a manager on the China In-Depth team at Decision Resources Group (DRG). Since 2016, he has specialized in market research and competitive intelligence in a range of diseases in diverse therapeutic areas, including non-small-cell lung cancer (NSCLC), amyotrophic lateral sclerosis (ALS), idiopathic pulmonary fibrosis (IPF), and rheumatoid arthritis (RA) at DRG. He has authored various research and analysis reports for the , EU5, and China markets, leveraging primary and secondary market research and real-world evidence. Prior to joining DRG, Akash was a postdoctoral fellow at the University of Massachusetts Medical School. He holds a from the International Centre for Genetic Engineering and Biotechnology in New Delhi and an from Jawaharlal Nehru University in New Delhi.
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.